2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2539

The Validity and Reliability of Turkish Version of the Jenkins Sleep Scale in Rheumatoid Arthritis
Abstract Number: 2540

Construct Validity of the Promis-29 in Systemic Sclerosis: Results from the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort
Abstract Number: 2541

Improving Adherence with Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Rationale and Design of the Traction Trial
Abstract Number: 2542

The Multidimensional Assessment of Fatigue Scale: A 25-Year Review and Evaluation
Abstract Number: 2543

Content Validity of the Improved Health Assessment Questionnaire in Knee Osteoarthritis Patients
Abstract Number: 2544

Representing the Variability in Patients’ Preferences
Abstract Number: 2545

Psychometric Testing of the Valued Life Activities Questionnaire in People with Rheumatoid Arthritis in the UK: Rasch Analysis
Abstract Number: 2546

Targeting Synovial Fibroblasts By the Intra-Articular Delivery of microRNA-140-3p and -5p Ameliorates Experimental Autoimmune Arthritis
Abstract Number: 2547

NIP-565, a Novel JAK1-Selective Inhibitor, for the Treatment of Rheumatoid Arthritis
Abstract Number: 2548

M-CSF-R Is a Critical Determinant for the Differentiation of Classical to Non-Classical Monocytes
Abstract Number: 2549

Characterizing the RPTPσ Mediated Proteoglycan Switch As a Target for Rheumatoid Arthritis Therapy
Abstract Number: 2550

Metabolomic Profiling of Joints in Murine Models of Inflammatory Arthritis
Abstract Number: 2551

Antibodies to Malondialdehyde-Acetaldhyde Adducts Are Increased in the Serum of Mice Following Infection with P. Gingivalis and/or Injection of Citrullinated Mouse Type II Collagen: a Model of Human Disease Response
Abstract Number: 2552

Alterations in the Colonic Microbiome Precede the Development of Murine Inflammatory Arthritis
Abstract Number: 2553

Involvement of M2 Macrophages in the Pathogenesis of Arthritis in a Mouse Model

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].